GREFFEX, INC.

AURORA, CO · CIK 0001439539 · Biotech · Private

Gene Transfer Vector Plug and Play Platform for gene therapy and vaccine development

greffex.com →
Grants
$337K
2 awards
Sector median: 1
Raised
$155K
1 Form D · Aug 2017
110 months since last filing
Contracts
—
No federal contracts on record
Patents
21
0 granted · 21 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$155,000
Federal grantDepartment of Health and Human Services · Phase I · Development of an Usher Gene Therapy$227,497
Federal grantDepartment of Health and Human Services · Phase I · Development of an Usher Gene Therapy$109,982
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2640Avant Sciences, Inc.—$175K
2641Renova Therapeutics, Inc.—$167K
2642BIONANOTECH LLC——
2643GREFFEX, INC.—$155K
2644RITROVA THERAPEUTICS INC.—$150K
2645SYMMETRIC COMPUTING, INC.——
2646Ajaya Bio, Inc.—$150K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • Jehan Al-MeerDirector
  • Sir Walter BodmerDirector
  • William ConnollyDirector · Executive Officer
  • John PriceDirector · Executive Officer
  • Uwe StaerzDirector · Executive Officer
  • Phillip ZobristDirector

Patents

USPTO · 0 granted of 21
  • Gene Therapy For Retinal Diseasesapplication
  • Design Of Optimized Universal Influenza Vaccines, Their Designs And Usesapplication
  • Antibody Constructs To Target T Cell Responses To Sars-cov Protein Expressing Cells, Their Design And Usesapplication
  • Multivalent Beta-coronavirus Vaccines, Their Designs And Usesapplication
  • Enhancement Of The Production Of Adenovirus-based Gene Transfer Vectorsapplication
  • Engineering Coronavirus Spike Proteins As Vaccine Antigens, Their Design And Usesapplication
  • Engineering Broadly Reactive Coronavirus Vaccines And Related Designs And Usesapplication
  • Maintaining Dna Fragments In Eukaryotic Cells, Approaches And Usesapplication
  • Replication-deficient Avian Adenoviral Vectors, Their Design And Usesapplication
  • Culture Systems For The Efficient Production Of Gene Transfer Vectorsapplication
  • Adenovirus-mediated gene therapy for retinal diseaseapplication
  • Culture Systems For The Efficient Production Of Gene Transfer Vectorsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.